A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer
Completed · Phase 1
Conditions studied: Advanced Cancer
In brief
This is a Phase 1 study during which patients with advanced/metastatic solid tumors will receive investigational study drug ARRY-334543 and capecitabine. Patients will receive increasing doses of study drug in combination with capecitabine in order to achieve the highest dose of study drug possible that will not cause unacceptable side effects. Patients will be followed to see what side effects the combination causes and what effectiveness the combination has, if any, in treating the cancer. Approximately 30 patients from the US and Canada will be enrolled in this study.
Key facts
- Study ID
- NCT00710736
- Run by
- Array Biopharma, now a wholly owned subsidiary of Pfizer
- People needed
- 29
- Starts
- 2008-06-01
- Expected to finish
- 2011-04-01
- Last updated by the study team
- 2020-10-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Colorado Cancer Center — Aurora, Colorado, United States
- Roswell Park Cancer Institute — Buffalo, New York, United States
- British Columbia Cancer Agency- Centre for the Southern Interior — Kelowna, British Columbia, Canada
- The Ottawa Hospital Cancer Centre — Ottawa, Ontario, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.